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Recent advances in the diagnosis and management 
of childhood acute promyelocytic leukemia
Since the successful introduction of all-trans-retinoic acid (ATRA) 
and its combination with anthracycline-containing chemotherapy, 
the prognosis for acute promyelocytic leukemia (APL) has markedly 
improved. With ATRA and anthracycline-based-chemotherapy, the 
complete remission rate is greater than 90%, and the long-term survi-
val rate is 70‒89%. Moreover, arsenic trioxide (ATO), which was in-
tro  duced for APL treatment in 1994, resulted in excellent remission 
rates in relapsed patients with APL, and more recently, several clinical 
studies have been designed to explore its role in initial therapy either 
alone or in combination with ATRA. APL is a rare disease in children 
and is frequently associated with hyperleukocytosis, which is a marker 
for higher risk of relapse and an increased incidence of microgranular 
morphology. The frequency of occurrence of the promyelocytic leu-
kemia/retinoic acid receptor-alpha (PML/RARα) isoforms bcr 2 and bcr 
3 is higher in children than in adults. Although recent clinical studies 
have reported comparable long-term survival rates in patients with 
APL, therapy for APL in children is challenging because of the risk of 
early death and the potential long-term cardiac toxicity resulting from 
the need to use high doses of anthracyclines. Additional prospective, 
randomized, large clinical trials are needed to address several issues 
in pediatric APL and to possibly minimize or eliminate the need for 
chemotherapy by combining ATRA and ATO. In this review article, 
we discuss the molecular pathogenesis, diagnostic progress, and most 
recent therapeutic advances in the treatment of children with APL.
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curable disease. These include the presence of life-threatening 
consumptive coagulopathy at diagnosis, high sensitivity of leukemic 
blasts to anthracyclines, and a balanced reciprocal translocation 
between chromosomes 15 and 17, t(15;17)(q22;q21), which results 
in a fusion between the promyelocytic leukemia (PML) gene on 
Introduction
Acute promyelocytic leukemia (APL) is a subtype distinct from all 
other acute myeloid leukemias (AMLs) with respect to the clinical, 
morphologic, cytogenetic, and molecular characteristics of a highly 96      ES Yoo, et al. • Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia
chromosome 15 and retinoic acid receptor-alpha (RAR alpha; 
RARα ) on chromosome 17. The ability of leukemic promyeloblasts 
to undergo differentiation into neutrophils with all-trans retinoic acid 
(ATRA) depends on the presence of the PML-RARα  fusion gene in 
leukemic cells
1, 2).
ATRA-based chemotherapy as a type of targeted therapy 
contributes to the best relative overall prognosis among pediatric 
AML subtypes, with a remission rate greater than 90% and a 5-year 
disease-free survival of approximately 80%
3-13). Moreover, arsenic 
trioxide (ATO), which was introduced in 1994 in APL, induces 
complete hematologic, cytogenetic, and molecular remissions via the 
dual effects of inducing partial differentiation and apoptosis of APL 
blasts
14-21). Single ATO trials have demonstrated excellent remission 
rates in relapsed patients with APL
14, 15), and more recently as front-line 
therapy either alone or in combination with ATRA
16-18). In pediatric 
cases, when single agent ATO was used in newly diagnosed pediatric 
APL patients, remission rates of 86% and 3-year EFS of 75% were 
reported
19-21).  However, there is very limited experience with the 
combination of ATRA and ATO as initial therapy in children with 
newly diagnosed APL. Treatment strategies continue to evolve 
rapidly, with a focus on minimizing cytotoxic chemotherapy and 
introducing ATO as part of initial therapy. This review will discuss 
the incidence, molecular pathogenesis, diagnostic and therapeutic 
progress, and future therapeutic perspectives of APL in children.
Epidemiology
APL accounts for only 5‒8% of pediatric AML cases. Approxi-
mately 600‒800 children and adolescents develop acute leukemia 
each year in the United States
22). In contrast to other subtypes of 
AML, which are equally represented across ethnic and racial groups, 
APL incidence varies widely among nations, with an increased 
incidence of APL in children from Italy and Central and South 
America
23). 
The age distribution of patients with APL differs from other forms 
of AML. While APL is uncommon in the first decade of life, the 
incidence increases during the second decade reaching a plateau 
during early adulthood; then the incidence remains constant until 
it decreases after 60 years of age. APL appears to be slightly more 
common in females.
Clinical presentations
APL more frequently presents with a higher incidence of hyper-
leukocytosis in children than in adults (approximately 40% in 
children vs. 20‒25% in adults)
24). It is caused by an increased 
incidence of microgranular (M3v) morphology, constituting up to 
25% of pediatric cases, and a more frequent occurrence of the PML-
RARα  isoforms bcr 2 and bcr 3 in children
25). Initial leukocyte count 
is the most important prognostic factor in patients with APL, and 
children with WBCs higher than 5,000/mm
3 or 10,000/mm
3 have 
a high risk of relapse
26). Compared to other types of AML, in APL, 
leukopenia is significantly more common, hepatosplenomegaly is 
less common, and central nervous system (CNS) involvement of 
leukemia is rare.
Bleeding secondary to disseminated intravascular coagulation 
(DIC) is a unique presentation at diagnosis or after the initiation of 
cytotoxic chemotherapy in patients with APL. It can cause a 10‒20% 
incidence of early death due to hemorrhage
27). The risk of DIC is 
higher in patients with the microgranular variant of APL. Starting 
treatment with a differentiation agent (e.g., all-trans retinoic acid 
[ATRA]) plus supportive care as soon as the diagnosis is suspected, 
irrespective of definitive cytogenetic or molecular confirmation, 
is important to rapidly improve the coagulopathy. Although the 
mechanism for APL-induced DIC is not fully understood, bleeding 
coagulopathy is caused by the enhanced fibrinolytic activity involving 
3 factors—tissue factor, cancer procoagulant, and increased annexin 
II receptor expression on the surface of the leukemic promyelocytes
28). 
Tissue factor forms a complex with factor VII to activate factors X 
and IX. Cancer procoagulant activates factor X. Annexin II receptor 
binds plasminogen and its activator, tissue plasminogen activator, 
thus increasing plasmin formation.
Molecular pathogenesis
More than 95% of APL patients have a balanced reciprocal 
translocation between chromosome 15q22 and 17q21, which results 
in a fusion between the PML gene and RARα  called PML-RARα . 
RARα  is encoded on the long arm of chromosome 17 (Fig. 1A)
29) 
and is a member of the retinoic acid (RA) nuclear receptor family that 
acts as a ligand-inducible transcription factor by binding to specific 
response elements (RARE) at the promoter region of target genes. 
It is mainly expressed in hematopoietic cells and has an important 
role in regulating gene expression. In the absence of RA, retinoic acid 
receptor (RAR) forms heterodimers with the retinoid X receptor 
(RXR), and the RA alpha gene is bound by the nuclear corepressor 
factor, thereby causing recruitment of the corepressor complex, 
chromatin condensation, and transcriptional repression. In the 
presence of RA, the genes are activated, and terminal differentiation 
of promyelocytes occurs. The promyelocytic gene (PML) is encoded 
on the long arm of chromosome 15 is thought to be involved in 
apoptosis and tumor suppression
29). Korean J Pediatr 2011;54(3):95-105 • DOI: 10.3345/kjp.2011.54.3.95    97
The breakpoint in chromosome 17 is consistently found in intron 
2. However, there are 3 possible isoforms caused by the translocation 
based on the PML breakpoint location in chromosome 15. The 3 
breakpoints in PML occur at intron 3 (L form), intron 6 (S form), and 
exon 6 (V form). Compared with the L form, the S form is associated 
with a shorter remission duration and overall survival (OS)
30).
PML-RARα  homodimerizes via the PML coiled-coil domain and 
causes the RAR to bind more tightly to the nuclear corepressor factor 
and histone deacetylases (HDACs) on RARα  target genes, thereby 
enforcing DNA methylation. Therefore, physiological doses of RA 
cannot activate the genes and induce repression of RA signaling, 
which blocks transcription and differentiation of granulocytes. 
Pharmacological doses of RA convert PML-RARα  into a transcrip-
tional activator, thus enhancing the expression of crucial RARα  
targets and restoring normal differentiation (Fig. 1B)
29).
In about 5% of cases, alternative rearrangements of chromosome 
17q21 with other gene partners are observed (Fig. 2). These include 
promyelocytic leukemia zinc finger (PLZF)/RARα  t(11;17)(q23;q21), 
nucleophosmin (NPM)/RARα  t(5;17)(q35;q12-21), nuclear mitotic 
apparatus (NuMa)/RARα  t(11;17)(q13;q21), and/or signal transducer 
and activator of transcription 5b (STAT5b)/RARα  t(17;17)(q11;q21). 
All of these rearrangements are ATRA-sensitive, except for PLZF/
RARα , which is not sensitive to ATRA or ATO
31).
Diagnostic work-up
1. Morphology
APL cells are morphologically different from normal promyelo-
cytes. These cells are larger and typically have creased, folded, bilobed, 
or kidney-shaped nuclei with heavy azurophilic granules and bundles 
of Auer rods (faggots). There are several main morphologic variants 
of APL. (a) The most common variant is the hypergranular or typical 
form, which accounts for approximately 75% of cases. The cytoplasm 
of these promyelocytes typically contains densely packed, bright-pink, 
reddish-blue, or dark-purple granules and frequently contains Auer 
rods, which are clumps of granular material containing lysosomes, 
peroxidase, lysosomal enzymes, and large crystalline inclusions. 
A
B
Fig. 1. A) Structure of the promyelocytic leukemia (PML), retinoic acid receptor-α (RARα), and the PML-
RARα fusion proteins. RING (R), B boxes (B), and coiled-coil (CC) domains in PML are indicated. The 
RARα DNA-binding domain (C) and hormone-binding domain (E) are shown. A, B, D, and F are other 
regulatory domains. PML-RARα retains the functional domains of both proteins, allowing dominant-
negative activities on both PML and RARα. B) PML-RARα homodimers bind and repress RARα targets 
through enhanced recruitment of corepressors. Retinoic acid (RA) converts PML-RARα into an activator 
and restores differentiation, yielding clinical remission. HAT, histone acetyltransferase; HDAC, histone 
deacetylase (From de The et al, Nat Rev Cancer 2010;10:775-83).
PML/RARα
t(15;17)(q22;q21) 
95%
RARα fusion proteins 
in APL 
Frequency 
(%) 
PLZF/RARα 
t(11;17)(q23;q21) 
1
NPM1/RARα 
t(5;17)(q35;q12-21) 
0.5
NuMa/RARα 
t(11;17)(q13;q21) 
<0.1
STAT5b/RARα 
t(17;17)(q11;q21 )
<0.1
PRKAR1A/RARα  <0.1
FIP1L1/RARα  <0.1
Fig. 2. Acute promyelocytic leukemia-associated RARα fusion protein.98      ES Yoo, et al. • Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia
Bundles of Auer rods, called faggot cells, are also seen occasionally. 
(b) The microgranular (hypogranular or agranular; M3v) variant 
accounts for approximately 25% of cases
32). These cells have bilobed 
nuclei and fine, dusky granules in the cytoplasm; Auer rods are rare. 
(c) The hyperbasophilic microgranular subtype has an increased 
nucleocytoplasmic ratio and strongly basophilic cytoplasm with 
cytoplasmic budding that mimics micromegakaryocytes. There are few 
granules and no Auer rods. (d) PLZF-RAR alpha (M3r) variants have 
regular, condensed chromatin in the nucleus. There are fewer granules, 
and Auer rods are rare compared with the hypergranular subtype.
2. Immunophenotype
Compared with other subtypes of AML, APL has distinctive 
immunophenotypic features such as frequent expression of CD13, 
CD33, and CD19; low or negative expression of CD34; and rare 
expression of CD117, HLA-DR, and CD11b. Unlike normal 
promyelocytes, APL cells express abnormally low levels of CD15
33). 
Fifteen percent of APL cases express the CD56 antigen at diagnosis, 
and in some studies, this has been associated with worse outcome
31). 
The pattern of hypogranular variants of APL is more hetero-
geneous, with a higher percentage of cells expressing the T-cell 
antigen CD2, the stem cell marker CD34, HLA-DR, and CD56. 
CD19 has also been correlated with the M3v form. CD34 expression 
was suggested as a reliable marker to distinguish between M3v and 
classic APL. Hyperbasophilic APL expresses HLA-DR, CD33, 
CD13, HLA-DR, CD34, CD2, and CD9.
3. Molecular and genetic diagnosis of APL
Identification of the specific genetic lesion in APL cells with 
t(15;17)(q22;q12);PML-RARA is feasible at the chromosome, 
DNA, RNA, and protein level using conventional karyotyping, 
fluorescence in situ hybridization (FISH) for PML/RARA, Southern 
blot, reverse-transcriptase polymerase chain reaction (RT-PCR) 
for PML-RARA RNA, and anti-PML monoclonal antibodies. In 
general, cytogenetic, FISH, and molecular analyses are attempted 
simultaneously. Karyotyping is highly specific and is an essential 
part of standard work-up, but it has the following disadvantages: 
good-quality metaphases are required, it is time-consuming, and 
cryptic rearrangements leading to PML-RARA will be missed 
(false negatives). However, rare molecular subtypes of APL, such 
as t(11;17), t(5;17), and other additional coexistent cytogenetic 
abnormalities can be detected. FISH is less expensive, highly specific, 
faster than conventional cytogenetics, and can usually be completed 
within 24 h; however, it does not provide information about the 
PML-RARA isoform detected and therefore cannot be used for 
the molecular monitoring of residual disease. In contrast, RT-PCR 
provides information on the PML breakpoint location (bcr 1, bcr 2, 
and bcr 3) in addition to the advantages of FISH. This is the current 
“gold standard” for confirming the diagnosis of APL and is very 
useful for assessing response and follow-up monitoring of minimal 
residual disease (MRD). However, RT-PCR has a long turn-around 
time (approximately 2 days) and can have both false positives 
(contamination artifacts) and false negatives (due to poor RNA yield). 
RT-PCR should be performed at presentation to precisely characterize 
the amplification target, even in patients with APL confirmed by 
cytogenetics and/or FISH. Southern blot is a highly specific DNA-
based method; however, it is now rarely used for APL diagnosis 
because it is laborious. Finally, indirect immunofluorescence or 
immunohistochemistry using anti-PML monoclonal antibodies 
is an easy method that allows for the rapid identification of the 
characteristic microgranular nuclear distribution of the PML protein 
in approximately 2 h, but is not widely used. However, sometimes the 
staining pattern of non-APL cases can be difficult to interpret.
Initial approach for suspected APL
APL usually presents as abrupt onset. The early mortality rate 
is high (10‒20%) because of hemorrhage from a characteristic 
coagulopathy. When a diagnosis of APL is suspected by the 
characteristic morphology of leukemic population, the disease 
should be managed as a medical emergency, because hemorrhagic 
complications within the first hours and days are frequent and can be 
lethal. The treatment must be started immediately with attention of 
following instructions. First, start ATRA therapy as soon as possible 
after reviewing peripheral blood and bone marrow, and even before 
definitive cytogenetic or molecular confirmation of the diagnosis 
has been made. Second, the administration of supportive care with 
fresh frozen plasma and cryoprecipitate or platelet transfusions should 
be started to maintain fibrinogen and platelets above 100‒150 mg/
dL and 20,000‒50,000/mm
3, respectively, until all clinical and 
laboratory signs of coagulopathy have disappeared. Immediate 
treatment with ATRA on the same day as diagnosis is suspected 
rapidly improves coagulopathy. Third, confirmation of APL 
diagnosis should be performed at the genetic level by demonstrating 
the presence of t(15;17) and PML-RARα .
Induction therapy for newly diagnosed APL patients
1. Standard front-line therapy
After the introduction of ATRA in APL therapy, Huang et 
al
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patients with APL in the late 1980s. In the early trials, tretinoin 
was administered as a single agent to induce remission followed by 
consolidation chemotherapy, but several studies showed that ATRA-
induced remissions were short-lived and had no effects on survival
35), 
suggesting the need to add chemotherapy during consolidation to 
obtain prolonged survival. More recent studies have shown that 
patients receiving ATRA followed by chemotherapy had significantly 
better outcomes than patients treated with chemotherapy alone. 
Furthermore, the European APL group showed improved outcomes 
in patients treated with simultaneous ATRA and chemotherapy 
than with sequential use
36). Since then, there have been several other 
multicenter trials based on the same concept, and simultaneous 
administration of ATRA and anthracycline-based chemotherapy 
is currently considered the standard induction treatment for newly 
diagnosed patients. This combination therapy gives a better quality of 
complete remission (CR) with rates of 90‒95% and is more effective 
in controlling ATRA-induced leukocytosis in newly diagnosed 
patients with APL. 
The type of chemotherapy that is more advantageous for im-
proving CR rates with ATRA is not clearly defined. Concerning 
the role of cytarabine, a randomized study was defined the patients 
treated with DNR+cytarabine had a better outcome than those 
treated with DNR alone
39). Another group observed that cytarabine 
gave a benefit to patients with WBC counts greater than 10,000/
mm
3 and was associated with better outcome
38). Therefore, this issue 
remains controversial. However, many clinicians still use ARA-C 
in combination with ATRA and anthracyclines. For anthracycline, 
most clinicians prefer IDA to DNR, but there is no prospective data 
showing any advantage for comparing IDA versus DNR. Possible 
therapeutic options for APL are summarized in Table 1.
Limited studies have reported therapeutic results using combi-
nations of ATRA and anthracycline-based chemotherapy in children 
with APL
3-13). In general, these studies showed improved outcome, 
with CR rates above 90% and a disease-free survival rate of 77%. 
These outcomes in children are comparable with those reported in 
adult patients. However, pseudotumor cerebri are observed more 
frequently in children than in adults during ATRA treatment, and 
a high cumulative dose of anthracycline resulted in increasing late 
cardiac toxicity in children. To decrease these risks, some groups have 
used a reduced dose of ATRA (e.g., 25 mg/m
2 instead of 45 mg/m
2), 
and a decreased incidence of pseudotumor cerebri with excellent 
results was reported at an ATRA dose of 25 mg/m
2/d than with 45 
mg/m
2/d in children and adolescents with APL
3-6). More prospective, 
randomized, large clinical trials are needed in children with APL.
Most newly diagnosed APL patients achieve CR with ATRA-
based induction chemotherapy followed by a complete molecular 
remission after consolidation therapy. Resistance to primary therapy 
in APL is extremely rare or absent, and this situation causes suspicion 
of incorrect diagnosis
39). The most frequent cause of induction failure 
is early death due to fatal cerebral hemorrhage. APL coagulopathy 
will clearly be improved by the addition of ATRA. The outcome of 
clinical trials in pediatric patients with APL treated with ATRA and 
anthracycline-based chemotherapy is summarized in Table 2.
2. Role of ATO in front-line therapy
ATO has proven to be another effective agent for APL therapy. The 
mechanism of action for ATO, which differs from that of ATRA, 
includes the induction of partial differentiation at low concentrations 
and apoptosis at higher concentrations in APL cells. Since ATO has 
been shown to induce remission in the treatment of relapsed APL, 
with observed remission rates of more than 80%
14, 15), several trials 
have explored the role of this agent in front-line therapy
16-21). Previous 
studies have shown that ATO with or without ATRA is equally 
effective in inducing remission in newly diagnosed patients with 
APL, and a CR rate of more than 85% and 5-year EFS and OS of 
more than 90% were reported
16-21). Zhou et al
21) reported an 89.5% 
CR rate, an 83.9% 5-year OS, and a 72.7% EFS in 19 children with 
newly diagnosed APL treated with single-agent ATO. These results 
demonstrate the high efficacy and minimal toxicity of ATRA+ATO 
treatment for newly diagnosed APL in long-term follow up, suggesting 
a new potential front-line therapy for de novo APL patients. 
Despite these promising results, the current recommendation for 
induction therapy in newly diagnosed APL is the standard approach 
with ATRA+chemotherapy. It might appear reasonable to consider 
the possibility of a randomized study comparing conventional 
treatment using ATRA+chemotherapy with ATO  alone or 
Table 1. Possible Options for treatment of Acute Promyelocytic Leukemia
Treatment Regimens in use
Induction ATRA+chemotherapy  
 : ATRA+anthracycline (IDA or DNR) 
                       ±Cytarabine
ATRA+ATO
ATO
Consolidation ATRA+Chemotherapy (Anthracycline±Cytarabine)
ATRA+ATO
ATO
GO
Maintenance  ATRA+6MP/MTX
Relapse/Refractory ATO
SCT
Abbreviations: ATRA, all-trans retinoic acid; ATO, arsenic trioxide; IDA, 
Idaribicin; DNR, Daunorubicin; GO, gemtuzumab-ozogamicin; 6MP, 6- 
mercaptopurine; MTX, methotrexate; SCT, stem cell transplantation100      ES Yoo, et al. • Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia
Table 2. Clinical Outcome of Newly Diagnosed Children with Acute Promyelocytic Leukemia by using ATRA-based Chemotherapy 
Group Induction Regimen
Consolidation Regimen
Maintenance Regimen
No
CR 
(%)
Outcome  Conclusion
German-Austrian-Swiss 
Mann et al.
 3)
(2001) 
ATRA+DNR or IDA
6-TG/PD/VCR/adriamycin/AraC/Cyclophosphamide
6TG+Cytarabine for I year
22 95 5-year EFS: NA
5-year OS: 87%
ATRA during induction can avoid early 
death and have better outcomes 
compared to conventional therapy.
European APL
De Botton et al. 
4)
(2004)
ATRA+DNR+AraC
3 course of DNR+AraC+ATRA
ATRA+6MP+MTX for 2 years
31 97 5-year EFS: NA
5-year OS: 90%
ATRA with chemotherapy for induction 
and maintenance has favorable results. 
GIMEMA
Testi et al.
5)
(2005)
ATRA+IDA (AIDA protocol)
Consolidation: Course 1: IDA+AraC
                       Course 2: MA+VP-16
                       Course 3: IDA+AraC+6TG
ATRA and/or Chemotherapy
124 96 5-year EFS: 78%
5-year OS: 89%
WBC count at diagnosis of greater than 
10,000/mm
3 is significant prognostic 
factor.
High efficacy and feasibility of the AIDA 
protocol in pediatric patients.
PETHEMA
Ortega et al.
6) 
(2005)
ATRA+IDA
3 courses of consolidation 
(ATRA+IDA, ATRA+MTX, ATRA+IDA dose up)
ATRA+6MP+MTX for 2 years
66 92 5-year EFS: 82%
5-year OS: 87%
High incidence of leukocytosis in 
children.
ATRA+IDA: comparable antileukemic 
effect
CALGB C9710
Powell et al.
7)
(2006)
ATRA+DNR or IDA
2 course of ATRA+DNR+AraC
ATRA±6MP±MTX for 1 year
64(2) 3-year EFS: 59%
3-year OS: 77%
EFS and OS in pediatric patients did not 
differ from those in adults without  ATO
Modified PETHEMA  
LPA99
Luo et al.
8)
(2009)
ATRA+DNR
4 course consolidation: 
  High dose AraC+MA+ATRA
No maintenance therpay
  Vs
ATRA+MA
3 course consolidation: ATRA+MA , ATRA+DNR, 
  ATRA+MA
ATRA+6MP+MTX for 1 year
30
(16/14)
56.3
92.9
3-year EFS: 37.5%
3.5-year EFS: 79.6%
Less intensive protocol is successful 
for reducing toxicity without increase of 
relapse risk.
North American 
Intergroup INT0129
Gregory et al.
9)
(2009)
ATRA vs DNR+AraC
2 course of consolidation: DNR+AraC
ATRA vs Observation 
53 81 5-year EFS: 41%
5-year OS: 69%
Significant DFS 
advantage by ATRA
ATRA during induction and maintenance 
has advantage of improving DFS.
Tunisia group 
Jeddi et al.
10)
(2010)
ATRA+Anthracycline based chemotherapy 20 95 4-year EFS: 75%
4-year OS: 75%
Comparable results with 
adults
ATRA+anthracyclin based chemo-
therapy in children has comparable 
results with those in adults.
AML-BFM Study Group
Creutzig et al.
11) 
(2010)
ATRA+IDA+Etoposide or AraC+DNR+Etoposide
3 course: ATAR with AraC+IDA, AraC+Ma, 
AraC+Etoposide
ATRA+6TG+AraC+IT AraC for 18 months
81 93 5-year EFS: 73%
5-year OS: 89%
Reduced cumulative 
dose of anthracycline 
(350 mg/m
2) was used 
safely
Reduced anthracycline dose with ATRA 
was safe to maintain high cure rate and 
to reduce toxicity. 
Japanese Group
Imaizumi et al.
12)
(2010)
ATAR+IDA+AraC
6 course of consolidation;
  HD AraC, 3 days+ATRA, 
  AraC+ATRA, 
  HD AraC, 5 days+ATRA
ATRA for 15 days, every 3 months, for 1 year
58 96.6 7-year EFS: 91.4%
7-year OS: 93.1%
ATRA, cytarabine and anthracycline-
based therapy was useful in childhood 
APL.
Korean Group
Kim et al.
13)
(2010)
ATAR+IDA
3 course of consolidation: 
  AraC+IDA/ MX+Etoposide/ AraC+IDA
ATRA+6MP+MTX for 2 years
23 87 EFS: 78.3%
OS: 76.3%
Abbreviations: ATRA, all trans retinoic acid; DNR, daunorubicn; IDA, idarubicine; MA, Mitoxantrone; AraC, Cytarabine; MTX, methotrexate; 6MP, 
6-mercaptopurine; EFS, event free survival; OS, overall survival.Korean J Pediatr 2011;54(3):95-105 • DOI: 10.3345/kjp.2011.54.3.95    101
ATRA+ATO to minimize the chemotherapy in patients with good 
or intermediate-risk disease.
3.  Evaluating response to induction therapy
An initial response to induction therapy can be determined with 
bone marrow aspiration and biopsy performed after the patient 
has recovered their absolute neutrophil count (>1,000/mm
3) and 
platelet count (>100,000/mm
3). However, morphologic, cytogenetic, 
and molecular follow up should be interpreted with caution in 
patients with APL during and soon after induction because the 
morphologic features of bone marrow receiving ATRA-containing 
regimens show a relatively hypercellular pattern. This reflects the 
residual differentiation of leukemic cells, and the persistence of 
atypical promyelocytes is occasionally detectable several weeks 
after the start of induction therapy with ATRA. Such features may 
be misleading as resistant disease. In these cases, ATRA-based 
treatment should be continued to obtain terminal differentiation 
of blasts and achieve hematological remission. To summarize, early 
morphologic, cytogenetic, and molecular assessments at the end of 
induction have no value for therapeutic decision making, and such 
assessments should wait until blasts have terminally differentiated and 
hematological remission has been achieved.
4. Consolidation therapy
The treatment strategy, including the type of consolidation and 
drug combination for post-remission therapy, is more controversial. 
Nevertheless, there is a consensus on the administration of at least 2‒3 
courses of anthracycline-based chemotherapy with or without Ara-C 
39). The molecular CR must be obtained after ending of consolidation 
therapy. More than 90‒99% of patients achieved molecular remission 
after receiving 2‒3 cycles of anthracycline-based chemotherapy
40). A 
small fraction of patients have persistent molecular disease at the end 
of consolidation and is needed to required additional, more intensive 
treatments, including hematopoietic stem cell transplantation 
(HSCT) when feasible. 
As in induction, the role of cytarabine also remains controversial 
in consolidation. A randomized clinical trial reported comparable 
CR rates for ATRA+idarubicin (IDA) and ATRA+daunorubicin 
(DNR+cytarabine regardless of differences in risk group
26).  However, 
there is a trend in favor of cytarabine administration for high-
risk of relapse patients (initial WBC count >10,000/mm
3) on the 
basis of published results, which have demonstrated an improved 
antileukemic effect for the cytarabine-included regimens and a 
reduced relapse rate in high-risk patients
40-42). In summary, the 
combination chemotherapeutic drugs including cytarabine is 
recommended for patients with an initial WBC count >10,000/mm
3 
who are at major risk of relapse.    
Although the benefit provided by the addition of ATRA to 
chemotherapy for consolidation is not confirmed, the GIMEMA 
and PETHEMA groups showed a statistically significant reduction 
in relapse risk by adding ATRA at the standard dose (45 mg/m
2/d for 
adults and 25 mg/m
2/d for children) in conjunction with 3 courses of 
consolidation chemotherapy for 15 days
24, 42).
It is not certain whether there is a benefit provided by the addition 
of ATO for post-remission therapy. Significantly better EFS and OS 
were reported with the use of ATO as post-remission treatment before 
the standard consolidation regimen with 2 more courses of ATRA 
+DNR or ATO
43). This result provides further support for the use of 
ATO for purpose of eliminating of chemotherapy in consolidation.
5. Maintenance therapy
The potential use of maintenance treatment is an unresolved 
question in APL patients with molecular-negative disease at the end 
of consolidation. European APL group conducted the advantage 
of ATRA for maintenance therapy in APL and showed a lower 
relapse rate by combination of intermittent ATRA, methotrexate 
(MTX) and 6-mercaptopurine (6MP)
44). But, more recent report by 
a Japanese study showed no any benefit of ATRA in maintenance 
therapy
45).
Studies to determine the role of ATRA-based maintenance 
therapy is still ongoing. The recommended schedule is to administer 
ATRA for 15 days at intervals of 3 months for 2 years. A therapeutic 
algorithm for newly diagnosed patients is proposed in Fig. 3.
6. Response assessment and MRD monitoring 
Unlike the assessment of response after induction therapy, mole-
APL is suspected by morphology
Start ATRA
immediately
Confirm molecular diagnosis
• Cytogenetics
• FISH
• RT-PCR
• Anti-PML immunostaning Supportive care
to decrease hemorrhage-associated mortality
Fibrinogen>100-150 mg/L / PLT>30-50x103/mm3 
Induction therapy
• ATRA (45 or 25 mg/m2/d PO) + Anthracycline ± Cytarabine
• ATRA + ATO + Anthracycline-based chemotherapy
• ATO
Consolidation therapy
• 2-3 cycles of ATRA(day1-15) + Anthracycline ± Cytarabine
• 2-3 cycles of ATO
Maintenance therapy
ATRA (45 or 25 mg/m2/d #2 PO for 15 days
+ weekly MTX +daily  6MP 
for 2 years
Molecular assessment by RT-PCR
at the end of consolidation
Molecular CR(+) Molecular CR(-)
More intensive therapy
ATO, allo/auto SCT
Genetically confirmed
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cular assessment of response after the completion of consolidation can 
be clinically relevant and is important to determine the risk of relapse, 
because the achievement of molecular remission at this time is a major 
treatment objective in APL patients. RT-PCR of PML-RARα  
in bone marrow with relatively low sensitivity, detecting 1 leukemic 
cell in 10
3 to 10
4 cells, is usually used to detect molecular remission. 
Patients who test PML-RARα  positive after consolidation have poor 
prognosis and a potential risk of rapid progression to overt relapse. 
To rule out false positives, BM is repeated for MRD assessment 
within 2 weeks. More aggressive salvage therapy with ATO and/or 
chemotherapy and allogeneic HSCT should be considered for these 
patients. In contrast, patients who test negative for PML-RARα  
after consolidation have a low risk of relapse and should undergo 
maintenance therapy. We need to consider how often molecular 
monitoring after consolidation therapy is appropriate. It is reasonable 
to determine the frequency of monitoring for MRD according to the 
initial risk of relapse. Conversion to PCR positivity for PML-RARα  
during remission is highly predictive of subsequent hematologic 
relapse and underlines the prognostic value of MRD.
Treatment-associated adverse events
1. APL differentiation syndrome 
A potentially life-threatening complication called differentiation 
syndrome (DS), formerly known as retinoic acid syndrome, occurs 
in 2.5‒30% of newly diagnosed APL patients receiving ATRA 
treatment. This syndrome has also been described in patients 
with relapsed APL who received induction therapy with ATO. 
DS usually develops during induction therapy with ATRA and/
or ATO, typically during the first 30 days of therapy. It is present 
neither during consolidation or maintenance therapy using 2 drugs, 
nor during ATRA treatment in non-APL malignancies. Leukemic 
APL cells might play a fundamental role in the development of DS. 
The clinical symptoms of DS are unexplained fever, cough, dyspnea, 
peripheral edema, weight gain, pleural fluid retention, interstitial 
pulmonary infiltrates, hypotension, pericardial effusion, and acute 
renal failure. This is often mistaken for fluid overload with pleural 
effusion or pneumonia, congestive heart failure, and diffuse alveolar 
hemorrhage. The syndrome usually develops within 2 weeks of 
therapy and is commonly associated with a rapidly rising leukocyte 
count. The probable risk factors for DS are a high leukocyte count 
and a rapidly increasing leukocyte count. This syndrome is associated 
with increased cytokine release from differentiating myeloid cells 
and modulation of adhesion molecules on the surface of aggregated 
APL blasts and vascular endothelial cells as a result of exposure to 
ATRA, which results in capillary leak and increased adherence to 
capillary endothelium. Steroid rapidly reduces these aggregations 
of APL cells. If DS is suspected or definitive, specific therapy with 
dexamethasone 0.3 mg/kg/dose twice daily in children (10 mg twice 
daily in adults) should be started immediately because this syndrome 
can be potentially life threatening, with a mortality rate as high as 
9% 
46). Early introduction of chemotherapy has significantly reduced 
this incidence of DS. A temporary discontinuation of ATRA and/
or ATO is indicated in severe case of DS. ATRA can be restarted in 
most cases once the syndrome has resolved.
2. Pseudotumor cerebri
Another complication of induction therapy with ATRA is 
pseudotumor cerebri (PTC), which is more commonly observed 
in children with APL than in adults, and occurs in 5‒15% of those 
enrolled in clinical trials
5, 6). It is characterized by increased intracranial 
pressure, severe headache, nausea, vomiting, and in severe cases 
by vision disturbances and papilledema. The mechanism of CNS 
toxicity by ATRA is not clear, but an excess of retinol is postulated to 
lead to a sustained increase in the choroidal secretion of cerebrospinal 
fluid or a decrease in its absorption by the arachnoid villi. Treatment 
of PTC is a temporary discontinuation or dose reduction of ATRA 
and the administration of dexamethasone, osmotic diuretics, and 
analgesics. To decrease these risks, some groups have used a reduced 
dose of ATRA (e.g., 25 mg/m
2 instead of 45 mg/m
2), and a decreased 
incidence of PTC with excellent results has been reported at an 
ATRA dose of 25 mg/m
2/d than with 45 mg/m
2/d in children and 
adolescents with APL
4).  
Prognostic factors in APL
The most important prognostic factor in patients with APL is 
leukocyte count at initial presentation. Children with WBCs higher 
than 5,000/mm
3 or 10,000/mm
3 have a high risk of relapse
26). FMS-
like tyrosine kinase 3 internal tandem duplications (FLT3/ITD), 
which are mutations in a tyrosine kinase receptor, have recently been 
considered as another prognostic indicator in pediatric APL. The 
incidence of FLT3/ITD mutations is 22.2% in non-APL patients, 
compared with 34.9% in children with APL
47). These mutations 
are often associated with hyperleukocytosis at diagnosis and higher 
mortality during induction therapy. The microgranular variant 
form of APL is frequently associated with FLT3/ITD. However, the 
clinical impact of these mutations on relapse rate or OS is not yet 
entirely clear, and more clinical studies are needed.Korean J Pediatr 2011;54(3):95-105 • DOI: 10.3345/kjp.2011.54.3.95    103
Treatment of relapsed APL patients
Although more than 80% of pediatric patients with newly 
diagnosed APL can be cured with ATRA-based therapy and primary 
drug resistance is extremely uncommon, 10‒15% of patients have 
a relapse, and 20‒30% of those have high-risk APL. Therefore, 
it is difficult to conduct randomized studies with ATRA-based 
chemotherapy and/or ATO-based treatment as salvage therapy. 
Only limited data are available, including small series. Several 
treatment regimens have been utilized to treat relapsed disease, 
including ATRA, anthracyclines, high-dose cytarabine, autologous 
or allogeneic HSCT, ATO, and gemtuzumab ozogamicin. However, 
in this setting, most physicians would recommend the use of ATO. 
The efficacy of ATO for the treatment of both newly diagnosed and 
refractory or relapsed patients with APL has been proven in adults 
and children
14, 15). These studies reported a second CR rate of 80‒90% 
and OS at 1‒3 years of 50‒70%. ATO is administered intravenously 
at a recommended dose of 0.15 mg/kg/d until hematologic remission, 
or for a maximum of 60 days. ATO is generally well tolerated, and 
only mild toxic effects have been reported in the majority of patients. 
However, more severe complications may occur, including DS and 
prolongation of the QT interval to a treatable degree. ATO can lead 
to molecular CR after relapse and can play a critical role prior to 
transplantation. 
Since the introduction of ATO, an additional course of ATO+ 
ATRA is recommended after achieving a second CR as consolidation 
therapy, and is followed by a molecular response after 2 cycles of 
ATO, to determine the continuation of therapy or risk of relapse. 
In a patient who is at higher risk, such as persistent PCR positivity, 
allogeneic HSCT should be done. Regarding the choice of autologous 
or allogeneic HSCT, both therapeutic options are feasible and have 
comparable outcomes
39).
Conclusion
Over the last 20 years since the introduction of ATRA, there 
have been remarkable advances at the laboratory and clinical level in 
treatment of APL. APL is the most curable disease and is a paradigm 
for successful targeted treatment. However, the treatment of APL 
in children is challenging because of the risks of early death and 
potential long-term cardiac toxicity resulting from the need to use 
high doses of anthracyclines. Moreover, information on the long-term 
outcome from randomized studies in children treated with ATRA 
and anthracycline-based chemotherapy is still limited. Up-front use 
of ATO, either in induction or consolidation, allows children to avoid 
conventional cytotoxic chemotherapy in the near future. Prospective, 
randomized large clinical trials are needed to address several issues 
in APL and to possibly minimize and eliminate chemotherapy by 
combining  ATRA and ATO.  
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